Synonym
L 767679; L-767679; L767679;
IUPAC/Chemical Name
(S)-3-(2-(1-oxo-7-(piperazin-1-yl)-3,4-dihydroisoquinolin-2(1H)-yl)acetamido)pent-4-ynoic acid
InChi Key
QTVKUFZTCJLGEJ-OAHLLOKOSA-N
InChi Code
InChI=1S/C20H24N4O4/c1-2-15(11-19(26)27)22-18(25)13-24-8-5-14-3-4-16(12-17(14)20(24)28)23-9-6-21-7-10-23/h1,3-4,12,15,21H,5-11,13H2,(H,22,25)(H,26,27)/t15-/m1/s1
SMILES Code
C#C[C@@H](NC(CN(CCC1=C2C=C(N3CCNCC3)C=C1)C2=O)=O)CC(O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
384.43
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Bednar B, Cook JJ, Holahan MA, Cunningham ME, Jumes PA, Bednar RA, Hartman GD, Gould RJ. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood. 1999 Jul 15;94(2):587-99. PubMed PMID: 10397726.
2: Prueksaritanont T, DeLuna P, Gorham LM, Ma B, Cohn D, Pang J, Xu X, Leung K, Lin JH. In vitro and in vivo evaluations of intestinal barriers for the zwitterion L-767,679 and its carboxyl ester prodrug L-775,318. Roles of efflux and metabolism. Drug Metab Dispos. 1998 Jun;26(6):520-7. PubMed PMID: 9616186.
3: Prueksaritanont T, Gorham LM, Yeh KC. Analysis of metabolite kinetics by deconvolution and in vivo-in vitro correlations of metabolite formation rates: studies of fibrinogen receptor antagonist ester prodrugs. J Pharm Sci. 1997 Dec;86(12):1345-51. PubMed PMID: 9423143.
4: Prueksaritanont T, Gorham LM, Breslin MJ, Hutchinson JH, Hartman GD, Vyas KP, Baillie TA. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate. Drug Metab Dispos. 1997 Aug;25(8):978-84. PubMed PMID: 9280406.
